Navigation Links
International Rett Syndrome Foundation awards $2M for cutting-edge Rett syndrome research
Date:10/1/2009

re micro-RNAs may be involved in the defects in neuronal maturation in Rett syndrome. This is a novel line of investigation with potentially high-impact results. The investigators have expertise in MeCP2 biology and strong preliminary data on two specific micro-RNAs that suggests these are the key microRNAs that are dysregulated in Rett syndrome with functional consequences and are very relevant to neuronal development. In the final phase of her project, Dr. Zhao will also conduct experiments that are aimed at functional rescue which lends a therapeutic aspect to this study.

Post Doctoral Fellowships

Cassiano Carromeu, PhD University of California San Diego (Mentor Alysson Muotri PhD)
Modeling Rett Syndrome with human pluripotent stem cells

Dr. Carromeu's project will be carried out in the laboratory of Dr. Alysson Muotri who has recently developed induced pluripotent stem cells (iPSCs) from Rett patients'skin cells. These iSPCs have been derived from patients with different MeCP2 mutations, and with different clinical phenotypes. The reprogrammed cells can generate a virtually unlimited supply of human neurons and other neural cell types of interest. In preliminary work, Dr. Carromeu showed that neurons generated this way displayed reduced synaptic contacts which are consistent with neuronal alterations seen in Rett syndrome. This model system will now be used for testing drugs to rescue these cellular alterations and to investigate developmental changes seen in Rett syndrome. Dr. Carromeu's mentor is the recent recipient of an NIH "New Innovator award." Dr. Muotri's research program seeks to use Rett syndrome as a model for other autism-spectrum disorders, this may reveal common molecular and cellular mechanisms present in different types of autism.

Jun Ren PhD, University of Alberta (Mentor John Greer PhD)
Investigation of Respiratory Dysfunction in a Mouse Model of Rett Syndrome

Dr.
'/>"/>

Contact: Dr. Antony Horton
212-459-2608
International Rett Syndrome Foundation
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology news :

1. International conference on endothelin
2. International event brings worlds top cancer doctors to Queens
3. Forest Service to host 2nd International Conference on Forests and Water in a Changing Environment
4. EMBO pioneers pension plan for internationally mobile postdoctoral researchers
5. International conference on CO2 sequestration processes
6. International research team seeks to unravel flatworm regeneration
7. Fujitsu PalmSecure Certified Under International Common Criteria Evaluation Assurance Level 2
8. Journal of Vascular and Interventional Radiology increases impact, international reach
9. International team of students and scientists on month-long field course in Siberian Arctic
10. ESHRE launches international study of polar body screening
11. International collaboration by scientists culminates in novel ion channels database
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... hospitals can collaborate on a surgery without having to ... in remote locations could receive immediate expert support from ... environment could soon become a reality thanks to research ... broadcast of surgeries using the advanced networking consortium Internet2. ...
... 2008─Bronx, NY─ In a breakthrough study appearing in advance ... Albert Einstein College of Medicine of Yeshiva University describe ... breast cancer cells for several days at a time. ... Center, provides detail on how cancer cells invade surrounding ...
... DURHAM, N.C. -- A new study led by Duke ... those that had been converted into farm fields -- ... that,s a good thing, say the study,s authors, because ... conditions. "It sounds counter-intuitive, but our study shows ...
Cached Biology News:The next step in health care: Telemedicine 2Einstein researchers develop a new way to study how breast cancer spreads 2Einstein researchers develop a new way to study how breast cancer spreads 3Shifts in soil bacterial populations linked to wetland restoration success 2Shifts in soil bacterial populations linked to wetland restoration success 3
(Date:4/27/2015)... VANCOUVER , April 27, 2015 /PRNewswire/ - iCo ... ICOTF), today reported financial results for the year ... are expressed in Canadian dollars and presented under ... year,s phase two DME results did not provide ... but extremely undervalued assets remain at iCo Therapeutics", ...
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... 2015 Editor Note: ... to bottom . Investor-Edge has initiated ... (NASDAQ: LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: ... SNTA ), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ... Free research report on Lexicon Pharma can be ...
(Date:4/27/2015)... Mass., April 27, 2015  Haemonetics Corporation (NYSE: ... fourth quarter fiscal 2015 of $226.5 million, down ... in the quarter. The Company reported a fourth ... $0.06 per share.  Adjusted net income, exclusive of ... was $24.5 million, up 1%, and adjusted earnings ...
Breaking Biology Technology:iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27
... and Addressing the ... Facing Clinical Labs Worldwide, ABBOTT PARK, Ill., April 4, ... of an initiative to,raise international awareness of the role played ... to improve,patient outcomes. Through a program called Labs Are Vital(TM), ...
... April 3, 2008 /Xinhua-PRNewswire-FirstCall/ --,Pharmaxis Ltd (ASX: PXS; ... trial in children with cystic fibrosis demonstrated excellent ... that,matched that achieved by the current marketed product ... on Bronchitol reflects that,seen in a previous study ...
... Inc. (Amex: ANX ) announced today that ... Directors, has joined the Company as,Executive Vice President, ... Executive Vice President, Mr. Bagnall will work with ... the Company,s,long-term strategy, help oversee internal execution of ...
Cached Biology Technology:International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative 2International Federation of Clinical Chemistry Forms Partnership With the Labs Are Vital(TM) Initiative 3Cystic Fibrosis Trial In Children Returns Positive Data 2Cystic Fibrosis Trial In Children Returns Positive Data 3Cystic Fibrosis Trial In Children Returns Positive Data 4ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 2ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 3ADVENTRX Creates Executive Vice President Position and Announces New Chief Financial Officer 4
... flexible and easy to use ... control all members of the ... features a clear and easy-to-follow ... setup, user-friendly and highly sophisticated ...
Strip Removal Tool 25/Box...
The bench-top stand comfortably holds up to 6 Finnpipette Digital single- and multichannel pipettes. The crossbars are made of a grippy material to keep the pipettes firmly in place. Individual shelf...
... Analysis Note: Protein determined by Biuret Physical ... mM Tris-HCl, pH 7.6, 1 mM MgCl ... Preparation Unit Definition: One unit will ... minute at pH 9.8 at 37 C. ...
Biology Products: